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Editorial
Percutaneous Occlusion of Atrial Septal Defect –  
As You Please!
Francisco Chamié
A trial septal defects (ASDs) correspond to 10% of birth defects in newborns and to 30% to 40% of defects in adults.1 Children are generally as-
ymptomatic, but only 4% of patients above 40 years 
deny symptoms.2
See page 384
Although ASDs are generally well tolerated, some 
complications can arise in adulthood; the most feared 
is the onset of lung vascular disease. Significant pul-
monary arterial hypertension can occur in approxi-
mately 22% of adults, with the possibility of vascular 
pulmonary hyper-resistance development in 15% of 
these patients.3 Other problems that may occur in the 
natural history of ASDs are: increase of right cavities 
with right ventricular dysfunction, systemic desatura-
tion, paradoxical embolism, and atrial arrhythmias, 
whose incidence increase with age.
Introduced in 1948 by Murray, the surgical cor-
rection of ostium secundum ASD is a well established, 
safe, and effective procedure, with a satisfactorily low 
mortality rate. However, it presents complications (major 
and minor), requires a longer hospitalization, causes 
pain, provokes visible scarring, and demands greater 
recovery time compared to percutaneous implants.4
Percutaneous occlusion, initially described by King 
and Mills in 1976, paved the way for modern interven-
tional cardiology to treat congenital defects, and it is 
perhaps the most commonly performed procedure in 
this field. The first report of percutaneous occlusion of 
an ostium secundum ASD in Brazilian literature was 
published by Haddad et al., in 1996.5 At that time, 
double disk prostheses without centralizing mechanism 
(Rashkind’s double umbrella, CardioSEAL®, StarFLEX®, 
and Sideris Buttoned Device®) prevailed. Difficult to 
handle, not repositionable, and with only reasonable 
results, these devices did not encourage Brazilian in-
terventionists, and their use was limited to a few cases 
in Rio de Janeiro and São Paulo.
The release of prostheses made of nitinol mesh 
(Amplatzer Septal Occluder® [ASO]; AGA Medical Corp. 
– Golden Valley, USA), in 1997, was responsible for 
an exponential increase in the number of procedures 
worldwide. The ASO was composed of fine nitinol wires 
forming two disks, and a central part that acted as an 
expansible centering mechanism, occupying the defect 
in its entirety, and corresponding to the nominal size 
of the prosthesis. It was a very elastic material and 
with large mechanical memory, allowing for the com-
pression of the devices into a long sheath, in order to 
restore their original shape when externalized. They had 
polyester flaps sutured at three points of the device, for 
the purpose of inducing thrombosis in its interior. The 
ASO prostheses also had major advantages compared 
to previous devices: they were able to occlude larger 
defects (up to 40 mm), did not need the aortic edge for 
fixation, were easy to handle, and were fully retrievable 
and repositionable while joined to the delivery cable, 
enabling a smaller learning curve. Thus, the ASO quickly 
became the device of choice for occlusion of ostium 
secundum ASDs worldwide. Its manufacturers obtained 
approval from the Food and Drug Administration (FDA) 
for use in the United States and are, to date, the most 
referred devices in the international medical literature.6 
The Brazilian experience with this device is vast and 
well documented.
Despite the excellent results presented, in association 
with the large number of implants, some problems arose: 
the emergence or worsening of headache, significant 
arrhythmias (especially total atrioventricular blocks 
[TAVB], and atrial fibrillation [AF]), late embolization 
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of the device, pericardial effusions, thrombi formation 
in the prosthesis’ left disc, and the extremely troubling 
erosions. General complications of the procedure with 
the use of the ASO are few (8.6%), but may occur 
immediately, or several years after its implantation.7
The ASO is composed of 55% nickel by weight, an 
element comprising part of the nitinol alloy. The release 
of nickel from the device starts immediately after its 
implantation and reaches its maximum in one month. 
This may cause allergic and toxic reactions in sensitive 
patients. While this has not proven to be a problem of 
great magnitude, some cases of occurrence or worsening 
of migraine in patients who underwent implantation of 
the ASO have been attributed to an allergic reaction 
to nickel. Alternatively, the platelet activation on the 
surface of the device has been proposed as a triggering 
mechanism of migraine; this hypothesis is supported by 
the therapeutic response to clopidogrel in some cases, 
but not in all. The stretching of the atrial septum caused 
by the presence of the device and leading to the release 
of atrial natriuretic peptide, a vasoactive antagonist of 
vasopressin, by myocytes, has been suggested as another 
theory for the onset of migraine.
The presence of atrial arrhythmias is not uncommon 
in patients with ostium secundum ASD. Electrophysi-
ological changes in the sinus node or in the system 
of atrial conduction may be due to a volumetric 
overload, or to the atrial distension in patients with 
hemodynamically significant ASDs and with increased 
right cavities. Studies with dynamic electrocardiogra-
phy (Holter) revealed no changes in basal rhythm in 
90% of patients after the procedure, but there have 
been changes in atrioventricular conduction in 7% of 
patients studied.
Other trials have demonstrated that the percutane-
ous occlusion with ASO may be associated with TAVB, 
which, in turn, may occur during or immediately after 
the procedure, requiring electrocardiographic monitoring. 
Nonetheless, most cases are transient, with spontaneous 
reversion; they mainly occur in defects that need the 
largest prostheses. The incidence of TAVB in children 
fluctuates at around 6% of cases. In adults, the inci-
dence is even lower, probably due to the larger size 
of the patients compared to the prostheses.
The onset of AF after the procedure entails increased 
risk of thromboembolic complications before a complete 
endothelialization of the device. The incidence of AF 
appears to increase after percutaneous occlusions of 
ostium secundum-type ASD, but this is also a well-
described complication in untreated patients. These 
data led some authors to speculate whether the pres-
ence of postprocedural AF would be a consequence 
of the device, or just a complication expected from 
the defect. Patients with pre-existing paroxysmal AF 
appear to only be able to maintain sinus rhythm after 
the occlusion of the defect. However, in isolation, the 
exclusive closure of the ASD does not appear to be 
able to produce these results, and the use of associated 
electrophysiological procedures becomes necessary.8
Device embolization has been reported in most case 
series, with an overall incidence of 0.1 to 3.5%. This 
complication can occur immediately or days, months, 
or years after implantation. When it occurs during the 
procedure, rescue can usually be performed by cap-
turing the device with a snare catheter and pulling it 
through a long sheath of larger size compared to that 
used for the implantation of the prosthesis. Some time 
after implantation, the device becomes rigid due to the 
formation of a thrombus inside it, and thus no longer 
allows for the capture and percutaneous removal. In 
such cases, the treatment option is surgical remotion, 
with elective closure of the defect, or as an emergency 
procedure.9 When embolized, the device tends to shift 
to the right atrium, from where it crosses the tricuspid 
valve and usually transits to the pulmonary trunk or its 
branches. Depending on its position relative to the axis 
of the vessel, it may not cause obstruction.
Pericardial effusions are described in most series, 
but without a convincing explanation for its apparition. 
These complications may occur immediately after the 
procedure, as a result of heart perforation, or days 
after the procedure, without a specific cause; but it is 
speculated that it may be due to an immune reaction.7
The presence of thrombi attached to the device, a 
complication feared due to its consequences, appears to 
be less frequent in nitinol mesh devices than in previ-
ously existing devices. Post-procedural AF and presence 
of atrial septal aneurysms appear to be predictive of 
thrombus formation, but dual antiplatelet therapy has 
been shown to be quite effective in preventing this 
complication.10
Erosions caused by ASO are rare, but potentially 
fatal events. These are unpredictable situations of extreme 
risk to patients, and can be of late occurrence. Although 
its mechanism is still unknown, erosion appears to be 
related to the abrasion of adjacent heart tissue by the 
metal prosthesis, and may have some facilitating agents, 
for instance, associated structural defects (as in Marfan 
syndrome), changes in tissue thickness and composition 
related to age, and variations in the ability of the tissue 
to resist to abrasive forces.11 Overestimation of the size 
of the device and contact of the edges of the prosthesis 
with the aortic or atrial wall, in association with heart 
movements, may act similarly to the mechanism of a 
circular saw.
The thickness of nitinol wire increases in certain 
sizes of this device (at 11, 18, 26, and 32 mm), to 
maintain its integrity and shape. Most erosions in the 
cases described occurred in patients who received the 
26 mm ASO, which is proportionally the most rigid 
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type for the nitinol wire thickness used in prostheses 
of 26-32 mm.12
In 2004, the estimated incidence of cases of erosion 
in United States using the ASO device was 0.1%. Other 
publications relate erosion rates ranging between 0.07 and 
0.28%, based on the number of ASOs sold or implanted. 
Clearly, these numbers are only estimates, since many 
patients do not have their implants registered, and many 
authors don’t report their complications; in any case, the 
incidence of this complication is fortunately low.
As to the time of appearance, erosions can occur 
days after implantation or up to six years after the 
procedure. The mortality rate caused by erosion varies 
from 0.004 to 0.015%.13 With respect to the location, 
the erosions reported occurred at the top (roof) of the   
right and left atria (with or without aortic involvement), 
in the aortic wall, and in the wall of both atria; in 
some cases, the site of the lesion was not identified. 
Erosions appear to be more frequent in defects of large 
diameter, located more superiorly, without aortic rim, 
and in those receiving oversized prostheses.13 Never-
theless, the majority of interventionists dedicated to 
the closure of ostium secundum ASDs believe that the 
primary culprit of the erosions is the movement of the 
prosthesis in the atrial septum.
Although the causes of erosion are not yet fully 
clarified, some recommendations were proposed  by 
a panel of experts in an attempt to minimize these 
episodes, such as avoiding the stretching of septum 
with the measuring balloon using the technique of 
flow occlusion (stop-flow), trying to identify patients 
at risk (high, large defects, without aortic rim), and 
closely following small pericardial effusions in the first 
24 hours after the procedure.14
The consensus is that, despite the complications 
reported, undoubtably the percutaneous occlusion of 
ostium secundum-type ASD with ASO is a safe and ef-
fective procedure. In the wake of the success of the AGA 
prostheses, a new generation of devices was released, 
aiming to correct deficiencies or introducing some in-
teresting modifications in the design of the prostheses, 
their composition, in the amount and thickness of the 
nitinol wire, in its external coating to prevent release 
of nickel, and in different release mechanisms. Unfor-
tunately, the number of publications in the literature 
worldwide focusing on these new devices is scarce, 
perhaps due to the fact that these devices have not 
been approved yet by the FDA. Even though most of 
these devices were approved by the Brazilian Health 
Surveillance Agency (Agência Nacional de Vigilância 
Sanitária [ANVISA]) and have been used in this coun-
try by several renowned experts with excellent results, 
the number of Brazilian publications on this subject is 
almost nonexistent. Thus, the publication of the article 
by Haddad et al.,15 in this issue of Revista Brasileira de 
Cardiologia Invasiva (RBCI) is quite auspicious, which 
reports the initial experience of the authors with a new 
prosthesis for closure of ostium secundum-type ASD.
For each of these new devices, there are advan-
tages and disadvantages regarding technical aspects and 
prosthesis profile. All of them are within our reach, and 
offer interesting options for safety, effectiveness, and 
reproducibility, so that the professional may choose the 
one that best fits his/her aims. Certainly, with the vari-
ous options currently available, the choice of prosthesis 
depends on the preference of the customer!
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